Innovative outcome measures coupled with a focus on patient-centered clinical differentiation can help the biopharma industry ...
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback